A Study of AK-01 (LY3295668) in Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Neoplasms|Neoplasm Metastasis|Triple Negative Breast Neoplasms|Head and Neck Neoplasms|Breast Neoplasms|Solid Tumor, Adult|Small Cell Lung Carcinoma
Interventions: DRUG: LY3295668
Sponsor: Eli Lilly and Company
Collaborators: AurKa Pharma Inc.